Systematic reviews on the prognostic role of biomarkers in heart failure

Marialena Trivella

Heart failure (HF) is characterised by high morbidity and mortality. The measurement of established biomarkers like the natriuretic peptide family (BNP, NT-proBNP, MR-proANP) and mid-regional proadrenomedullin (MR-proADM) may improve prognostic stratification and timely treatment for HF patients. We propose a series of five systematic reviews to identify and appraise prognostic studies of these biomarkers, and explore their added prognostic value for HF patient-relevant outcomes.

The reviews will be carried out following the conduct and reporting standards of Cochrane exemplar prognostic reviews. We will use novel prognostic model development and evaluation methodology in these reviews. We aim to make recommendations for future design and conduct of HF prognostic studies. These results may increase clinician awareness of prognostic modelling, leading to biomarkers-guided HF therapy. This may improve patient outcomes by ensuring intensive treatment is begun proactively rather than reactively in identified HF patients.

 

British Heart Foundation

Source of Funding

The British Heart Foundation aims to win the fight against cardiovascular disease.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley, Lorem Ipsum is simply dummy text of the printing and typesetting industry.